Group 1 - The Hong Kong stock market continued its strong performance in the first half of 2025, attracting mainland enterprises, particularly from Zhejiang, which saw 9 companies successfully listed [1][2] - A total of 42 new stocks were listed on the Hong Kong stock exchange in the first half of 2025, representing a 40% year-on-year increase, with total fundraising reaching a new high since 2021, surpassing 87.6 billion HKD for the entire year of 2024 [2][5] - Zhejiang enterprises accounted for the highest number of listings, with a total of 9 companies raising 14.4 billion HKD, a significant increase from just 1.016 billion HKD in the same period of 2024 [2][3] Group 2 - The listed Zhejiang companies span various sectors, including healthcare, consumer goods, and manufacturing, showcasing a diversified development trend [2][3] - Notable companies that went public include Sanhua Intelligent Control, which is a global leader in thermal management, and Cao Cao Travel, the largest ride-hailing platform in Hong Kong [2][4] - The trend of "A+H" dual platform listings is emerging, with leading A-share companies accelerating their listings in Hong Kong, exemplified by Sanhua Intelligent Control's recent IPO [3][4] Group 3 - The Hong Kong IPO market achieved the highest global fundraising amount in the first half of 2025, totaling 102.1 billion HKD, driven by international capital and supportive policies from both mainland and Hong Kong [5] - The market's internationalization provides direct support for enterprises, facilitating access to diverse overseas financing channels and enhancing global strategic layouts [5][6] - Expectations for the second half of 2025 indicate continued market heat, with projected fundraising of 200 billion HKD, primarily in technology, media, and consumer sectors [6]

证券研究报告·策略报告·策略深度报告 策略深度报告 20250701 7 月港股金股：利好落空后的利好 2025 年 07 月 01 日 [Table_Tag] [观点Table_Summary] ◼ 5 月开始，金管局因港币触及强方保证，下场干预，资金入港，hibor 利 率下跌，投资者觉得是利好。后来发现，这些进来的资金并没有大幅流 入股票，利好变成利空。两个月前阶段性卖出股票离场的资金，因为一 直没有等到市场下跌，在时间成本影响下，不得不在近期再次买入股票， 或将利好港股。 -此前利好：5 月份，资金入港， hibor 下跌，投资者预计增量资金入场。 -转落空：投资者发现，入港资金的投资去处，是存款、套息交易、债券、 打新股和加密货币等。这些资金并没有大幅投资二级市场股票。即使打 新股，上市后就立刻卖出。比如，海天味业获得超过 60 倍认购，但上 市后价格持平，没有上涨。说明部分资金在上市便锁定收益，并不停留 在股市上。 -或将转利好：有些资金仍然会依据过去三年的经验，在市场高位卖出， 然后等待市场下跌后再买入。经历了 5 月香港大规模资金入场，压低利 率后，转为利空，市场迟迟没有下跌。直到现在，这些资 ...

【环球网财经综合报道】上半年正式收官，港股IPO市场热度持续攀升。数据显示，今年上半年港交所完成43宗IPO项目，同比增加13家，增幅 43.33%；募资总额达1067.13亿港元，较去年同期增长688.54%，超2024年全年募资额。 谈及港股IPO火热原因，高盛亚洲相关人士指出，中国经济刺激政策带动全球投资者关注中国资产，监管支持力度大，上市企业质量高。中信证 券研报预计，A股公司港股发行潮或在2025年下半年，多家A股上市公司将分拆子公司赴港上市。 展望下半年，德勤预计2025年全年香港新股市场80只新股融资2000亿港元，除25只"A+H"新股外，多数项目来自科技、传媒、电信及消费业。德 勤相关负责人表示，若无重大负面干扰，对香港2025年争取全球IPO市场领先地位持审慎乐观态度。（陈十一） 从单个项目募资规模看，募资超100亿港元的IPO项目有宁德时代、恒瑞医药、海天味业3家；募资20亿至100亿港元的有三花智控等5家。 港交所上市通道迎来申报热潮，截至6月30日，220家企业处于IPO排队状态，较2024年同期显著增长，仅6月27日就有16家内地企业递表申请主板 上市，其中科技行业占10家。 "A ...

Group 1 - The core point of the article is the announcement of a 0.2% dividend for the Hong Kong Dividend ETF (159331), with the record date on July 3 and payment date on July 8 [1] - Huachuang Securities highlights that high-dividend sectors in the Hong Kong stock market can maintain dividend capabilities and shareholder returns due to stable free cash flow generation, especially in a context where inflation has not yet returned [1] - Companies with abundant free cash flow can sustain dividend performance and convert capital expenditures into elevated ROE, showcasing both defensive and growth characteristics [1] Group 2 - Traditional industries such as banking, ports, and highways are emphasized for their stable earnings and dividends, making them attractive in a low-interest-rate environment [1] - Industrial metals benefit from destocking and demand recovery, while telecom operators are experiencing accelerated free cash flow release due to maturing projects and increasing industry penetration, positioning them as scarce "growth-type cash flow" assets [1] - The Hong Kong stock market is noted for its lower valuations compared to the A-share market and a higher proportion of foreign investment, making it more appealing for international capital allocation, especially in a context of a weakening dollar [1] Group 3 - The Hong Kong Dividend ETF (159331) has distributed dividends for 11 consecutive months since its listing, indicating its potential as a monthly dividend fund [1] - Investors without stock accounts are encouraged to consider the Cathay CSI Hong Kong Stock Connect High Dividend Investment ETF Initiated Link A (022274) and Link C (022275) [1]

以下文章来源于东四十条资本 ，作者鲁智高 东四十条资本 . 聚焦股权投资行业人物、事件、数据、研究、政策解读，提供专业视角和深度洞见 | 创投圈有趣的灵魂 将投中网设为"星标⭐"，第一时间收获最新推送 46名员工，一年入账超11亿元。 作者丨 鲁智高 来源丨 东四十条资本 肖战代言的椰子水，刚刚上市了。 6月30日，IFBH Limited（下称"IFBH"）正式登陆港股。刚一开盘，这家拥有if椰子水品牌公司的股价涨超63%，市值超过 120亿港元。 招股期间，他们获得众多投资者追捧。据市场消息透露，IFBH已获得23.8万人认购，超购2690倍，涉资3148亿港元。 与此同时，包括瑞银集团、南方基金、广发国际、工银理财、对冲基金Jain Global等在内，IFBH的基石投资人达到11家。此 外，农夫山泉创始人钟睒睒旗下道合承光私募等投资机构也出现在这家公司的打新超额配售名单中。 在泰国富二代彭萨克（Pongsakorn Pongsak）的带领下，仅有46名员工的IFBH通过在中国、新加坡等地卖椰子水等产品， 一年的收入就超过11亿元。 目之所及，一大批消费公司正涌向港股。最近半年，海天味业、绿茶餐厅、布鲁 ...

港股创新药助力公募基金夺取2025年"中考"冠军。 2025年公募基金产品"中考"放榜，医药主题基金成为业绩排名大赢家。今年一季度期间，一度霸屏的人形机器 人赛道基金产品全部淡出十强，当前排名中期业绩前十的产品中有七只为医药主题基金，且这些医药主题基金 产品均大比例持有港股仓位，同时重仓单一行业的赛道化打法也主导基金业绩格局，前十的基金产品中仅有一 只基金产品在持仓上采取"均衡"策略。 排名今年全市场"中考"业绩十强的诺安价值精选基金经理唐晨认为，港股创新药仓位对基金产品至关重要，应 重点把握具备重磅炸弹潜力的大单品赛道，尤其是肿瘤、代谢性疾病、自身免疫病这三大赛道的创新药需求刚 性，因此也具有更大的投资机会。 人形机器人赛道基淡出 公募基金产品2025年上半年十强业绩今日出炉，以人形机器赛道为核心仓位的基金产品未能进入业绩十强。 在上述排名前十强的公募基金产品"中考"尖子生名单中，医药主题基金产品占据了七个名单，仅有中信建投基 金旗下的北交所精选基金、华夏基金旗下的北交所精选基金，以及广发基金旗下的广发成长领航基金为非医药 主题基金产品，这三只基金产品核心股票仓位未涉及医药。 此外，上述十强基金产品中，有9 ...

Core Viewpoint - Hebei Asset Management Co., Ltd. has submitted its initial public offering (IPO) application to list on the Hong Kong Stock Exchange, marking the first attempt by a local Asset Management Company (AMC) to go public in Hong Kong [1][12]. Group 1: Company Overview - Hebei Asset was established on November 24, 2015, and is the only local AMC in Hebei province authorized to acquire and manage non-performing financial assets [2]. - The company is under the supervision of the Hebei Provincial Financial Management Bureau and has a unique policy advantage as the only licensed local AMC in the province [2]. - As of the end of 2024, Hebei Asset's total assets are valued at 7.556 billion RMB, with a debt of 5.039 billion RMB, resulting in a debt-to-asset ratio of approximately 66.69% [2]. Group 2: Financial Performance - Hebei Asset's revenue from non-performing asset management has shown significant volatility, with a 130% year-on-year increase in 2024, reaching 512 million RMB, while in 2023, the revenue was only 222 million RMB, a 48% decline [7]. - The company reported a profit of 204 million RMB in 2024, recovering from a loss of 145 million RMB in 2023 [8]. - The revenue breakdown for 2024 indicates that 86.2% came from the disposal of non-performing assets, while restructuring and consulting services contributed 13.7% and 0.1%, respectively [4][5]. Group 3: Market Position and Industry Context - Hebei Asset holds a 24.4% market share in the local non-performing asset management sector, ranking second in the province, and a leading 47.2% market share in acquiring non-performing assets from small and medium-sized banks [2]. - The market size for non-performing asset management in Hebei province is projected to grow from approximately 222.2 billion RMB in 2024 to 322 billion RMB by 2029, with a compound annual growth rate of 7.7% [3]. - The company aims to leverage its first-mover advantage and professional expertise to support high-quality economic development in Hebei province [3].

Core Viewpoint - Shanghai Magnesium Health Technology Group Co., Ltd. (referred to as "Magnesium Health") has officially launched its IPO process on the Hong Kong Stock Exchange after completing seven rounds of financing, with a total financing amount of 3.137 billion yuan [2][4]. Financing and Shareholding Structure - Magnesium Health has raised a total of 3.137 billion yuan through seven rounds of financing since 2018, with significant participation from 38 shareholders, including major stakeholders like Shanghai Pharmaceuticals and Ant Group [2][4]. - The largest financing round occurred in August 2021, raising over 2 billion yuan, with participation from 23 global investors [4]. Financial Performance - The company is currently in a loss-making state, with net losses of 446 million yuan, 288 million yuan, and 76 million yuan projected for 2022, 2023, and 2024 respectively [2][7]. - Despite the losses, the company has shown a narrowing trend in its losses over the years, indicating potential for future profitability [2][7]. Market Position and Growth Potential - As of the end of last year, Magnesium Health is the largest provider of innovative drug and device solutions in China, with a projected revenue of 2.035 billion yuan for 2024 and a compound annual growth rate of approximately 38% [6]. - The demand for innovative health insurance services is expected to grow significantly, with a projected compound annual growth rate of 21% from 2024 to 2030 [8]. IPO Outlook - Industry insiders estimate that if Magnesium Health completes its IPO in the second half of the year, it could become the largest IPO on the Hong Kong Stock Exchange for that period [3][5]. - The IPO process typically takes 6-12 months, but Magnesium Health may expedite this timeline due to favorable market conditions [5]. Industry Trends - The Hong Kong IPO market is experiencing a resurgence, with a significant increase in the number of new listings and total funds raised compared to the previous year [10]. - There are currently over 170 IPO applications being processed in Hong Kong, indicating a robust pipeline for future listings [11].

Core Viewpoint - FWD Group Limited is currently conducting an IPO, aiming to raise approximately HKD 29.53 billion to enhance its capital levels and support growth initiatives [5] Group 1: IPO Details - FWD Group plans to offer 91.34 million shares at an issue price of HKD 38 per share, with 10% allocated for public offering and 90% for international offering [1] - The IPO subscription period is from June 26 to July 2, 2025, with shares expected to start trading on July 7, 2025 [1] - The company has secured cornerstone investors including Abu Dhabi sovereign fund's asset management company MC Management and Japan's T&D Life Insurance, with a total subscription amount of USD 250 million [1] Group 2: Market Opportunity - The total underwriting premium for the life insurance market is projected to grow from approximately USD 407 billion in 2023 to USD 579 billion by 2033, indicating significant market potential [2] - FWD Group's distribution channels include bancassurance, agents, brokers, and independent financial advisors, contributing 46.6%, 15.2%, 31.8%, and 6.5% respectively to new business value in 2024 [2] Group 3: Financial Performance - The company has experienced significant fluctuations in performance, with net insurance and investment results of approximately USD 493 million, USD 47 million, and USD 911 million for the years 2022, 2023, and 2024 respectively [2] - Corresponding net profits for the same years were -USD 320 million, -USD 717 million, and USD 10 million [4] Group 4: Debt and Financial Health - As of April 30, 2025, FWD Group has total borrowings of USD 2.786 billion, including USD 989 million in bank loans and USD 1.479 billion in subordinated notes [4] - The company also has outstanding perpetual securities with a face value of USD 950 million and a book value of USD 759 million [4] Group 5: Use of IPO Proceeds - The net proceeds from the IPO will be utilized to enhance the capital levels under the insurance group regulatory framework and to provide growth funding for operational entities [5]

我发现港股红利低波ETF（520550）今年1月15日刚成立，截至6月底不足半年的时间已经36次刷新新 高，涨幅达到16.78%，在所有申万一级行业中仅次于军工。 在今年一波三折的市场中，这只ETF就像一匹黑马，持续吸引资金涌入，目前已经连续18周实现净流 入，成立以来规模暴增108%。 它跟踪的是恒生港股通高股息低波动指数。这个指数最新股息率7.93%，成分股平均股息率6.47%，远 超A股红利指数的5%-6%和不足2%的10年期国债收益率，甚至38%的成分股股息率超过7%。 在低利率时代，这样的"现金奶牛"属性无疑极具吸引力。 2025年刚过去一半，南向净买入港股的规模就已经超过2024年全年的80%，并且重点加仓银行、能源等 高股息板块，其中银行股年内获南向净买入超过2000亿。 保险资金的配置需求同样旺盛。 新政策要求险资从2025年起提高股市投资比例，红利资产因分红稳定、波动低，成为险资及养老金 的"标配底仓"。在"资产荒"背景下，港股高息股成了优化收益的利器。 港股红利低波ETF（520550）本身采用的是全市场最低综合费率0.2%（管理费0.15%+托管费0.05%）， 长期持有能显著降低成本， ...